期刊文献+

帕利哌酮缓释片与奥氮平治疗精神分裂症患者的对照研究 被引量:2

A controlled comparison study on paliperidone extended-release tablets and olanzapine in the treatment of schizophrenia
原文传递
导出
摘要 目的:比较帕利哌酮缓释片与奥氮平治疗精神分裂症患者的疗效和安全性。方法:对156例精神分裂症患者随机分成帕利哌酮缓释片组和奥氮平组。采用简明精神病评定量表(BPRS)和不良反应症状量表(TESS),于治疗前、治疗1周、2周、4周和8周分别评定疗效和不良反应。结果:帕利哌酮缓释片组和奥氮平组的有效率分别为68.75%和65.78%,无显著差异。帕利哌酮缓释片组起效快,治疗1周后BPRS评分即显著下降,与奥氮平组有显著性差异(P<0.05),治疗8周后BPRS评分差异也有统计学意义(P<0.05)。帕利哌酮缓释片组不良反应轻微且低于奥氮平组。帕利哌酮组常见不良反应(发生率≥5%)为泌乳、闭经和便秘;奥氮平组(发生率≥5%)常见不良反应主要为镇静嗜睡、体重增加、血糖异常、头昏、便秘和转氨酶升高。结论:帕利哌酮缓释片与奥氮平对改善精神分裂症患者的有效率相当,但帕利哌酮缓释片起效迅速,不良反应少且轻微。 Objective: To evaluate the efficacy and safety of paliperidone extended-release (ER) tablets compared with olanzapine in the treatment of patients with schizophrenia. Methods: A randomized, controlled clinical trial was conducted. All 156 hospitalized patients with schizophrenia were treated with paliperdone ER or olanzapine for 8 weeks. The efficacy was evaluated by the total score changes in the brief psychiatric rating scale (BPRS) and the treatment emergent symptoms scale (TESS). All patients were assessed at the baseline, and the 1st, 2nd, 4th and 8th week. Results: The effective rate of treatment was 68.75% in paliperdone ER group and 65.78% in olanzapine group, with no statistically significant difference between the two groups. However, paliperidone ER had faster onset than olanzapine, with a significantly reduction in BPRS in the 1st and 8th weeks (P 〈 0.05). The adverse effects of paliperidone were lower and milder than those of olanzapine. The common adverse reactions of paliperdione group(occurance rate ≥5% ) were lactation or amenorrhoea, and constipation; the common adverse reactions of olanzapine group (occurance rate≥5% ) were sedation or somnolence, weight gain, glucose abnormalities, dizziness constipation and transaminase elevation. Conclusion : Paliperidone ER has similar effective rate with olanzapine. However, paliperidone ER has faster onset, lower and milder adverse effects than olanzapine.
机构地区 泉州市第三医院
出处 《中国新药杂志》 CAS CSCD 北大核心 2012年第22期2658-2661,共4页 Chinese Journal of New Drugs
关键词 精神分裂症 帕利哌酮缓释片 奥氮平 疗效 不良反应 schizophrenia paliperidone extended-release (paliperidone ER) tablets olanzapine efficacy adverse effect
  • 相关文献

参考文献17

  • 1MOLLER HJ. Antipsychotic agents. Gradually improving treat- ment from the traditional oral neuroleptics to the first atypical depot[ J ]. Eur Psychiatry, 2005, 20 (5 - 6) : 379 - 385.
  • 2LUBLIN H, EBERHARD J, LEVANDER S. Current therapy is- sues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics [ J ]. Int Clin Psy- chopharmacol, 2005, 20 ( 4 ) : 183 - 198.
  • 3KRYZHANOVSKAYA LA, XU W, MILLEN BA, et al. Com- parison of long-term ( at least 24 weeks) weight gain and meta- bolic changes between adolescents and adults treated with olanza- pine[ J ]. J Child Adolesc Psychopharmacol, 2012, 22 ( 2 ) : 157 - 165.
  • 4CONLEY R, GUPTA SK, SATHYAN G, et al. Clinical spec- trum of the osmotic-controlled release oral delivery system(OROS), an advanced oral delivery form [ J ]. Curr Med Res Opin, 2006, 22(10): 1879- 1892.
  • 5CHWIEDUK CM, KEATING GM. Paliperidone extended release : a review of its use in the management of schizophrenia [ J ]. Drugs, 2010, 70(10): 1295-1317.
  • 6MELTZER HY, BOBO WV, NUAMAH IF, et al. Efficacy and tolerability of oral paliperidone extend-release tablets in treatment of acute schizophrenia: pooled data from three 6-week, placebo- controlled studies[ J]. J Clin Psychiatry,2008, 69 (5) : 817 - 829.
  • 7DAVIDSON M, EMSLEY R, KRAMER M, et al. Efficacy, safe- ty and early response of paliperidone extended-release tablets (paliperdone ER): results of a 6-week, randomized, placebo- controlled study [ J ]. Schizophr Res, 2007, 93 ( 1 - 3 ) : 117 - 130.
  • 8张鸿燕,李华芳,王刚,等.帕利哌酮缓释片治疗急性精神分裂症疗效及安全性的对照研究[J].中华精神科杂志,2011,24(6):441-443.
  • 9余翔,廖节凤,许佳燕.帕利哌酮缓释片与奥氮平治疗首发精神分裂症患者的对照研究[J].临床精神医学杂志,2011,21(4):270-271. 被引量:17
  • 10SEEMAN P. Targeting the dopamine D2 receptor in schizophreni- a[J]. Expert Opin Ther Targets, 2006, 10(4) : 515 -531.

二级参考文献18

  • 1Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the management of schizophrenia [ J ]. Drug, 2010,70 : 1295-1317.
  • 2Leon JD, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone[ J]. Psychosomatics ,2010,51:80-88.
  • 3喻东山.精神疾病临床治疗手[M].南京:江苏科学技术出版社,2009:11.
  • 4Si T, Shu L, Si Y, et al. Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects [ J ]. Hum Psychopharmacol Clin Exp,2010,25:404-409.
  • 5Ortegal, Perez-RuixoJ P, StuyckensK, et al. Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia:meta-analysis of randomized, controlled clinical trials [ J ]. J Clin Pharmacology ,2010,50:293-310.
  • 6Ryosuke Arakawa,Hiroshi Ito,Akihiro Takano,Hidehiko Takahashi,Takuya Morimoto,Takeshi Sassa,Katsuya Ohta,Motoichiro Kato,Yoshiro Okubo,Tetsuya Suhara.Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia[J]. Psychopharmacology . 2008 (2)
  • 7BERWAERTS J,,CLETON A,HERBEN V,et al.The effects ofparoxetine on the pharmacokinetics of paliperidone extended-re-lease tablets. Pharmacopsychiatria . 2009
  • 8MELTZER HY,BOBO WV,NUAMAH IF,et al.Efficacy andtolerability of oral paliperidone extended-release tablets in thetreatment of acute schizophrenia:Pooled data from three 6-week,placebo-controlled studies. Clinical Child Psychology and Psychiatry . 2008
  • 9SCHREINER A.A flexible-dose study of paliperidone ER innon-acute patients with schizophrenia previously unsuccessfullytreated with other oral antipsychotics. 2nd Schizophrenia In-ternational Research Conference . 2010
  • 10CANUSO CM,TURKOZ I,SHEEHAN JJ,et al.Efficacy andsafety of paliperidone extended-release in schizophrenia patientswith prominent affective symptoms. Journal of Affective Disorders . 2010

共引文献57

同被引文献17

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部